FundLens
29
Pharma & HealthcareAvoid

Quant Healthcare

Quant · Direct–Growth · rank #17 of 18 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
24.6%
+21.6% vs index
3 Years
22.1%
+10.5% vs index
5 Years
Since launch
23.4%

Year-by-year performance

last entry = YTD
2024
+31.9%
2025
-3.6%
2026
+23.9%

Why this score

Quant Healthcare scores 29/100 — #17 of 18 Pharma & Healthcare fund (Avoid). It stands out for alpha — beating 72% of peers on alpha. The main drag is its volatility (better than only 3% of peers).

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

Volatility17.38 · 3rd percentile in category
Expense ratio1.51% · 3rd percentile in category
3Y return22.08% · 32nd percentile in category
Sharpe ratio0.89 · 22nd percentile in category
Sortino ratio1.24 · 23rd percentile in category
Alpha9.70 · 72nd percentile in category

Top holdings

top 5 = 48.1% of portfolio
1.Divi's Laboratories Ltd. 25.08.20269.93%
2.Glaxosmithkline Pharmaceuticals Ltd9.93%
3.Concord Biotech Ltd.9.66%
4.Zydus Wellness Ltd9.33%
5.Aster DM Healthcare Ltd9.25%

14 disclosed equity positions · portfolio as of Jul 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds